Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Holger Fritsch"'
Publikováno v:
Clinical Therapeutics. 42:2214-2224
Purpose This drug–drug interaction study determined whether the metabolism and distribution of the Polo-like kinase 1 inhibitor, volasertib, is affected by co-administration of the P-glycoprotein and cytochrome P-450 3A4 inhibitor, itraconazole. Me
Publikováno v:
Therapeutic Innovation & Regulatory Science
Volasertib is a selective cell cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). A potential for prolonged QT intervals was indicated with volasertib in preclinical studies and preliminary clinical
Autor:
Karin G. Haug, Angele Fleury, Iñaki F. Trocóniz, Belén P. Solans, Matthias Freiwald, Holger Fritsch
Publikováno v:
Clinical pharmacokinetics. 57(3)
Volasertib, a potent and selective polo-like kinase inhibitor, has shown to increase response rates and improve survival with a clinically manageable safety profile, administered alone and in combination with cytarabine in patients with acute myeloid
Autor:
Florian Voss, Hartmut Döhner, Carsten Müller-Tidow, Joseph M. Brandwein, Pascal Turlure, Konstanze Döhner, Oumedaly Reman, Michael Lübbert, Walter Fiedler, Johan Maertens, Holger Fritsch, Emmanuel Raffoux, Richard F. Schlenk, Stéphane Leprêtre, Oliver G. Ottmann, Tillmann Taube, Alwin Krämer, Alf Haaland, Loic Fouillard
Publikováno v:
Blood. 124:1426-1433
Treatment outcomes for older patients with acute myeloid leukemia (AML) have remained dismal. This randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy compared low-dose cytarabine (LDAC) with or without v
Autor:
Holger Fritsch, John J. Mahoney, Daniel P. Petrylak, Peter P. Lee, Wu Chou Su, Charles Zhao, Peter Rosen, David J. Vaughn, Charles Schloss, Walter M. Stadler, Guru Sonpavde, Marc S. Ernstoff, Michael A. Carducci, Chia-Chi Lin, Scott T. Tagawa, Richard Vinisko, Alexander I. Spira, Korinna Pilz, Nicholas J. Vogelzang, Sanjiv Modi
Publikováno v:
Cancer. 120:976-982
BACKGROUND Polo-like kinases (Plks) control multiple steps during the cell cycle, and Plk1 is overexpressed in urothelial cancer (UC). Volasertib (BI 6727), a Plk inhibitor, has demonstrated antitumor activity in several malignancies, including UC. I
Autor:
Mark A. Socinski, Quincy Chu, Leena Gandhi, Joe Stephenson, David M. Ellison, Mark M. Awad, Ramaswamy Govindan, Holger Fritsch, Gerd Munzert, Philip Bonomi, Daniel S. Bradford, Keith D. Eaton, Bruce E. Johnson
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 104
Objectives This phase II, open-label study was designed to evaluate the response rate to the polo-like kinase 1 (Plk-1) inhibitor BI 2536 in patients with sensitive-relapsed small cell lung cancer (SCLC). Secondary endpoints included progression-free
Autor:
Claude Petit, Vasthala Juvvigunta, Julie M. Vose, Holger Fritsch, Edmund K. Waller, Jonathan W. Friedberg, Anas Younes, Gerd Munzert, Bruce D. Cheson
Publikováno v:
Leukemia & Lymphoma. 54:708-713
Polo-like kinase 1 (Plk1) is expressed during mitosis and overexpressed in multiple cancers, including non-Hodgkin lymphoma (NHL). This phase I study determined the maximum tolerated dose (MTD) of BI 2536, a Plk1 inhibitor, as a 1 h infusion once eve
Autor:
Cornelia Schepers, Holger Fritsch, Regina Sennewald, Sebastian Härtter, Jeffrey Friedman, Sybille Baumann
Publikováno v:
European Journal of Clinical Pharmacology
Purpose To evaluate the pharmacokinetic and pharmacodynamic effects of concomitant administration of single loading doses of clopidogrel or multiple doses of clopidogrel with multiple doses of dabigatran etexilate. Methods This was an open-label tria
Autor:
Patrick Schöffski, Holger Fritsch, Patricia Glomb, Ahmad Awada, Pascal Wolter, Gerd Munzert, Herlinde Dumez, S. Bartholomeus, M. Taton, Thierry Gil
Publikováno v:
European Journal of Cancer. 48:179-186
Background Volasertib (BI 6727) is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase (Plk). This phase I dose-escalation study evaluated the maximum tolerated dose (MTD) of vola
Autor:
Alexander Staab, Holger Fritsch, Matthias Freiwald, Iñaki F. Trocóniz, Gerd Munzert, C Döge, Elena Soto
Publikováno v:
Clinical Pharmacology & Therapeutics. 88:660-667
This study investigated the feasibility of predicting the neutropenia-related effects of a therapy that combines the investigational drug BI 2536 (inhibitor of Polo-like kinase 1) and pemetrexed, an approved anticancer drug. Predictions were arrived